# Structural Studies and Drug Discovery Illuminate Serotonin Pharmacology

> **NIH NIH R35** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2021 · $423,752

## Abstract

Project Summary/Abstract
The main goal of the lab is to provide detailed structural and functional insight into serotonin signaling and
transport, and elucidate how drugs and medications modulate receptor and transporter function. Serotonin (5-
hydroxytryptamine, 5-HT) regulates much of human physiology in- and outside the CNS, including cognition,
mood, endocrine function and cardiovascular development. However, despite 5-HT's physiological and medical
importance, atomic-level insight into the mechanisms of 5-HT signaling and transport, and how drugs interact
with these molecular targets, has remained largely elusive. This lack of understanding has led to drug safety
issues in the past, and greatly hindered the exploration of many 5-HT targets for novel therapeutic applications.
Our lab is thus focused on two grossly understudied 5-HT targets. The first major direction of the lab is to
elucidate ligand binding and activation of the 5-HT1E receptor, the least understood 5-HT receptor whose
physiological role is unknown. Unlike for all other 5-HT receptors, there are no selective compounds for 5-
HT1ER, which raises important questions about the molecular architecture of its binding pocket and
mechanisms of receptor activation. To answer these questions, we will determine the cryoEM structure of G
protein-coupled 5-HT1ER, which will provide detailed structural insight into the ligand binding pocket
architecture, and the receptor's conformational changes responsible for G protein activation. The second major
project is focused on the vesicular monoamine transporter 2 (VMAT2), an essential transporter for storage and
regulation of neurotransmitter signaling, and target for a variety of disorders from diabetes to amphetamine
abuse. Despite its biological and medical significance, there is a lack of atomic-level insight into where and
how substrates, drugs, or medications bind, or how they modulate VMAT2 function. We will therefore
determine crystal structures of VMAT2 bound to various substrates and drugs, elucidate fundamental
mechanisms of transport and drug modulation, and characterize the precise architecture of different binding
sites. We will further use our molecular insights in structure-based drug discovery, to develop
pharmacologically and chemically novel tool compounds for future studies of VMAT2 (patho)biology in in vitro
and in vivo. Our studies are both innovative technically and conceptually, as the unique combination of
structural, pharmacological, and drug discovery approaches will provide an unprecedented view into the
molecular mechanisms of two neglected and understudied 5-HT drug targets.

## Key facts

- **NIH application ID:** 10149350
- **Project number:** 5R35GM133504-03
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Daniel Wacker
- **Activity code:** R35 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $423,752
- **Award type:** 5
- **Project period:** 2019-08-01 → 2024-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10149350

## Citation

> US National Institutes of Health, RePORTER application 10149350, Structural Studies and Drug Discovery Illuminate Serotonin Pharmacology (5R35GM133504-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10149350. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*